Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058705 · ClinicalTrials.gov registry record · NA
Near Infrared Fluorescence Imaging for Bladder Cancer Detection
A NA study of Bladder Cancer, sponsored by Edward Messing.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03058705 is a NA study of Bladder Cancer that has completed, run by Edward Messing. The registered enrollment target is 10 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03058705, a NA study of Bladder Cancer, has completed, sponsored by Edward Messing.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
Conditions Studied
Interventions
- DRUG Hexaminolevulinate HCL
- DEVICE Near Infrared Fluorescence (NIRF)
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-07-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03058705
The ClinicalTrials.gov registry entry for NCT03058705 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Edward Messing, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hexaminolevulinate HCL is the first listed.
NCT03058705 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03058705 about?
NCT03058705 is a clinical study titled "Near Infrared Fluorescence Imaging for Bladder Cancer Detection". The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
What is the current status of trial NCT03058705?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-11-28. Estimated completion is 2018-07-25.
What conditions does trial NCT03058705 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT03058705?
The interventions under investigation include: Hexaminolevulinate HCL (DRUG), Near Infrared Fluorescence (NIRF) (DEVICE).
Who is sponsoring clinical trial NCT03058705?
This trial is sponsored by Edward Messing, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03058705 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.